Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Maillet

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Cancers|June 28, 2023
Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell CarcinomaClaire Masson, Jonathan Thouvenin, Philippe Boudier, et al.
Anti-Cancer Drugs|December 11, 2012
Influence of statistician involvement on reporting of randomized clinical trials in medical oncologyJulien Péron, Benoit You, Hui K Gan, et al.
Cancers|February 15, 2022
Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/- DocetaxelAurore Carrot, Reza-Thierry Elaidi, Olivier Colomban, et al.
Cancers|February 11, 2023
Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients' Outcomes?Jonathan Thouvenin, Claire Masson, Philippe Boudier, et al.
JCO Clinical Cancer Informatics|February 16, 2024
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANAAurore Carrot, Stéphane Oudard, Olivier Colomban, et al.
Medicina (Kaunas, Lithuania)|February 26, 2025
Cutaneous Anguillulosis During Immunotherapy for Metastatic Renal Cell CarcinomaPierre Cornillon, Marie Beguinot, Denis Maillet, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2019
Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapiesPauline Corbaux, Mévidette El-Madani, Michel Tod, et al.
Journal of the National Cancer Institute|July 5, 2012
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic reviewJulien Péron, Gregory R Pond, Hui K Gan, et al.
International Journal of Cancer|January 18, 2019
A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitorsPatrick Arnaud-Coffin, Denis Maillet, Hui K Gan, et al.
Urologic Oncology|March 1, 2026
Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder studyFabien Moinard-Butot, Jean-Baptiste Barbe-Richaud, Edwige Baudry, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Cancers|June 28, 2023
Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell CarcinomaClaire Masson, Jonathan Thouvenin, Philippe Boudier, et al.
Anti-Cancer Drugs|December 11, 2012
Influence of statistician involvement on reporting of randomized clinical trials in medical oncologyJulien Péron, Benoit You, Hui K Gan, et al.
Cancers|February 15, 2022
Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/- DocetaxelAurore Carrot, Reza-Thierry Elaidi, Olivier Colomban, et al.
Cancers|February 11, 2023
Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients' Outcomes?Jonathan Thouvenin, Claire Masson, Philippe Boudier, et al.
JCO Clinical Cancer Informatics|February 16, 2024
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANAAurore Carrot, Stéphane Oudard, Olivier Colomban, et al.
Medicina (Kaunas, Lithuania)|February 26, 2025
Cutaneous Anguillulosis During Immunotherapy for Metastatic Renal Cell CarcinomaPierre Cornillon, Marie Beguinot, Denis Maillet, et al.
European Journal of Cancer (Oxford, England : 1990)|September 4, 2019
Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapiesPauline Corbaux, Mévidette El-Madani, Michel Tod, et al.
Journal of the National Cancer Institute|July 5, 2012
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic reviewJulien Péron, Gregory R Pond, Hui K Gan, et al.
International Journal of Cancer|January 18, 2019
A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitorsPatrick Arnaud-Coffin, Denis Maillet, Hui K Gan, et al.
Urologic Oncology|March 1, 2026
Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder studyFabien Moinard-Butot, Jean-Baptiste Barbe-Richaud, Edwige Baudry, et al.
Pageof 7